MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Oral [14C]PF-07220060
Drug: Oral PF-07220060
Drug: IV [14C] PF-07220060
First Posted Date
2024-02-20
Last Posted Date
2024-05-14
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT06267963
Locations
🇳🇱

PRA Health Sciences, Groningen, Netherlands

A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2024-02-13
Last Posted Date
2025-01-21
Lead Sponsor
Pfizer
Target Recruit Count
15
Registration Number
NCT06256510
Locations
🇧🇪

Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

Phase 2
Completed
Conditions
SARS-CoV-2 Infection
COVID-19
Influenza, Human
Interventions
Biological: BNT162b2 (Omi XBB.1.5)
Biological: RIV
Biological: BNT162b2 (Omi XBB.1.5)/RIV
Other: Normal saline placebo
First Posted Date
2024-02-01
Last Posted Date
2024-10-03
Lead Sponsor
Pfizer
Target Recruit Count
645
Registration Number
NCT06237049
Locations
🇺🇸

GW Vaccine Research Unit, Washington, District of Columbia, United States

🇺🇸

Optimal Research, Peoria, Illinois, United States

🇺🇸

GW Medical Faculty Associates, Washington, District of Columbia, United States

and more 24 locations

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Phase 1
Recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2024-01-22
Last Posted Date
2025-05-20
Lead Sponsor
Pfizer
Target Recruit Count
87
Registration Number
NCT06215118
Locations
🇦🇺

Calvary Mater Newcastle, Waratah, New South Wales, Australia

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

and more 28 locations

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris
Drug: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
First Posted Date
2024-01-16
Last Posted Date
2025-03-21
Lead Sponsor
Pfizer
Target Recruit Count
42
Registration Number
NCT06205407
Locations
🇺🇸

Clinical Trials of Texas, LLC, San Antonio, Texas, United States

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Phase 1
Active, not recruiting
Conditions
Breast Cancer
Interventions
First Posted Date
2024-01-16
Last Posted Date
2025-05-01
Lead Sponsor
Pfizer
Target Recruit Count
65
Registration Number
NCT06206837
Locations
🇺🇸

Highlands Oncology, Rogers, Arkansas, United States

🇺🇸

Highlands Oncology Group, Springdale, Arkansas, United States

🇺🇸

Hoag Health Center Irvine, Irvine, California, United States

and more 50 locations

Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data

Active, not recruiting
Conditions
SARS-CoV-2
COVID-19 Vaccines
Interventions
Biological: Vaccination
First Posted Date
2024-01-10
Last Posted Date
2024-06-04
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT06199934
Locations
🇺🇸

Pfizer Global Headquarters, New York, New York, United States

A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-01-05
Last Posted Date
2024-06-13
Lead Sponsor
Pfizer
Target Recruit Count
40
Registration Number
NCT06190561
Locations
🇺🇸

Anaheim Clinical Trials, LLC, Anaheim, California, United States

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

Phase 1
Active, not recruiting
Conditions
Pneumococcal Disease
Interventions
Biological: Multivalent Pneumococcal Vaccine - Formulation 1
Biological: Multivalent Pneumococcal Vaccine - Formulation 2
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological: Licensed pneumococcal comparator vaccine
First Posted Date
2023-12-26
Last Posted Date
2024-12-30
Lead Sponsor
Pfizer
Target Recruit Count
418
Registration Number
NCT06182124
Locations
🇺🇸

Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States

🇺🇸

Indago Research & Health Center, Inc, Hialeah, Florida, United States

🇺🇸

Clinical Research Atlanta, Stockbridge, Georgia, United States

and more 11 locations

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

Phase 1
Active, not recruiting
Conditions
Grippe
Influenza
Vaccines
Interventions
Biological: pdmFlu vaccine
Biological: Placebo
Biological: Licensed influenza vaccine
First Posted Date
2023-12-21
Last Posted Date
2025-06-03
Lead Sponsor
Pfizer
Target Recruit Count
157
Registration Number
NCT06179446
Locations
🇺🇸

Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

🇺🇸

Research Centers of America ( Hollywood ), Hollywood, Florida, United States

🇺🇸

NYU Langone Health, New York, New York, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath